Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Fat composition

An oil composition and oil technology, which are applied in the directions of edible phospholipid composition, pharmaceutical composition, edible oil/fat, etc., to achieve the effects of improving circulatory function, improving central nervous system function, and improving vision.

Inactive Publication Date: 2007-01-17
WAKUNAGA PHARMA CO LTD
View PDF4 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, until now, there is no known composition of glycerophospholipid-type docosahexaenoic acid, etc., and α-linolenic acid or oils and fats containing this linolenic acid.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0044] ICR female mice (3 weeks old) just after weaning were fed with n-3 series polyunsaturated fatty acid (about 3% α-linolenic acid / total lipid) or n-3 series polyunsaturated Feed the fatty acid-deficient diet (about 0.04% α-linolenic acid / total lipid) to obtain normal-growing mice or mice with insufficient intake of n-3 series polyunsaturated fatty acids. At the age of 8 weeks, they were mated with 9-week-old ICR male mice to obtain second-generation mice. The obtained second-generation pups were fed within 2 days of birth, with 10 pups per female, and the same feed was used thereafter. When the second generation was 7 weeks old, PS-DHA (phosphatidylserine with docosapentaenoic acid as structural fatty acid) was prepared to dissolve in linoleic acid (safflower oil: relative to 1 part of α-linolenic acid, linoleic acid 780 parts of oleic acid) and PS-DHA dissolved in α-linolenic acid (linseed oil: relative to 1 part of α-linolenic acid, the ratio of linoleic acid is 0.46 p...

Embodiment 2

[0049] Freshly weaned ICR strain female mice (3 weeks old) were given diets containing n-3 series polyunsaturated fatty acids (about 3% α-linolenic acid / total lipid) or containing n-3 series polyunsaturated fatty acids deficient The feed (about 0.04% α-linolenic acid / total lipid) was fed to obtain normal-developing mice or mice with insufficient intake of n-3 series polyunsaturated fatty acids. At the age of 8 weeks, they were mated with 9-week-old ICR male mice to obtain second-generation mice. The obtained second-generation pups were fed within 2 days of birth, with 10 pups per female, and the same feed was used thereafter. When the second generation was 7 weeks old, the drug to be tested was orally administered according to Example 1 once a day, and after the 2.5th week of starting to take it, within 11 days until the 4th week, the method of avoiding the dark (step through) type learning experiment, the results are shown in Table 2.

[0050] (Darkness Avoidance Type Learn...

Embodiment 3

[0055] The embodiment of embodiment 3PC-DHA

[0056] In the same manner as in Example 1 and Example 2, the second-generation ICR-series mice were obtained from mice with insufficient intake of n-3 series polyunsaturated fatty acids. When the second-generation male mice were 10 to 13 weeks old, the oil composition of PC-DHA dissolved in linoleic acid and the oil composition of PC-DHA dissolved in α-linolenic acid were prepared according to the daily intake DHA 11mg, PC 11mg respectively, measure the plasma DHA after 2 hours and the DHA in the plasma and red blood cells on the 5th day after 4 days of continuous administration. The results are shown in Table 3.

[0057] table 3

[0058] test group

[0059] It can be seen from Table 3 that, as in Example 1, PC-DHA also showed the result that when PC-DHA was dissolved in α-linolenic acid, DHA was absorbed rapidly and transferred to the tissue when DHA was insufficient as the initial state. It is known that PC-DHA can ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A composition which enables an n-3 type fatty acid having two or more unsaturated bonds to be absorbed into the body in a high degree and to move to issues in a high degree and can sufficiently produce the pharmacological activity of the fatty acid. It is a fat composition comprising: one or more phospholipids containing as a constituent fatty acid an n-3 type fatty acid having two or more unsaturated bonds which is selected among docosahexaenoic acid, docosapentaenoic acid, and eicosapentaenoic acid; and alpha-linolenic acid and / or a fat containing alpha-linolenic acid.

Description

technical field [0001] The present invention relates to an oil composition containing phospholipids with n-3 series polyunsaturated fatty acids such as docosahexaenoic acid as structural fatty acids, alpha-linolenic acid and / or oils containing alpha-linolenic acid. Background technique [0002] Marine animal oils such as fish oil and seal contain large amounts of docosahexaenoic acid (DHA), docosapentaenoic acid (DPA), and eicosapentaenoic acid (EPA). They are all n-3 series polyunsaturated fatty acids, and as a common pharmacological effect, it is reported that they have the effect of reducing neutral fat and inhibiting platelet aggregation. It has been reported that docosahexaenoic acid also has pharmacological effects such as improving memory and learning ability, improving vision, anti-inflammation, and lowering plasma cholesterol. Docosahexaenoic acid can prevent arteriosclerosis, improve cancer or rheumatism, etc. Pharmacological effects. Eicosapentaenoic acid has pha...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C11C3/00A61K31/202A61K31/683A23D9/00A23L1/30A23J7/00A61P25/20A61P25/28A23D9/007A23D9/013A61K36/00A61K45/06
CPCA23D9/013A23V2002/00A61K31/202A61K36/00A61K31/683A23L1/3006A23D9/00A23D9/007A61K45/06A23L33/115A61P9/00A61P25/00A61P25/20A61P25/28A61P27/02A23V2250/1842A23V2250/1868A23V2250/1882C11B11/00C11C3/00
Inventor 守口彻佐佐木彻行原马明子
Owner WAKUNAGA PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com